North America Fluorescent Immunoassay Market Forecast to 2028

North America Fluorescent Immunoassay Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (ELISA, Rapid Lateral Flow Immunoassay, and Others), Application (Infectious Diseases, Oncology, Cardiovascular Diseases, and Others), and End User (Hospitals & Clinics, Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others)

Report Code : BMIRE00025665 | Region : North America | Industry : Biotechnology | Published Date : 10/Aug/2022

The North America fluorescent immunoassay market is expected to grow from US$ 1,072.41 million in 2021 to US$ 1,598.58 million by 2028; it is estimated to register a CAGR of 5.9% from 2021 to 2028.

Fluorescent immunoassays are diagnostic tools for quality control and the quantity-specific detection of antigens and antibodies. The technique derives from the fundamental immunological concept of antigen-antibody binding. These are used in screening to quantify the production or inhibition of antigens/haptens associated with a disease target. These antigens or haptens are characteristic of the disease process and are mediated by the target, such as cytokines or growth factors. Cell therapy is the practice of using cellular material to produce the desired effect in vitro or in vivo through their biological activities and properties. The cells used for the treatments can be classified as either allogeneic or autologous. Modern cell-based therapies also include regenerating human cells, tissue, or organs. The basis of the cells used comes from the stem and progenitor cells, mature and functionally differentiated cells, or artificially produced tissue. Fluorescence-activated cell sorting (FACS) is a highly flexible technique with many options for stem cell sorting. It is also the only way to isolate a particular stem cell population using multiple internal and external markers. FACS is a specialized type of flow cytometry that sorts a heterogeneous mixture of cells based on each cell's specific light scatter and fluorescence properties. Cells are first tagged with fluorescent antibodies that bind to relevant proteins on target cells. Single cells pass a laser beam, and a detector measures fluorescence, forward scattered light (FSC), and side spread light (SSC). FSC and SSC are used to determine the size of the cell. Fluorescence at multiple wavelengths can be detected simultaneously but depends on the instrument's specific lasers, filters, and detectors. The cells are then physically sorted into different bins based on captured measurements and user-entered parameters. Fluorescence-activated cell sorting allows for current and future need for cell isolation to conduct efficient stem cell research. Thus, there is a growing demand for fluorescent immunoassays for providing quality and quantity-specific detection of antigens and antibodies.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America fluorescent immunoassay market at a notable CAGR during the forecast period.

North America Fluorescent Immunoassay Market Revenue and Forecast to 2028 (US$ Million)

North America Fluorescent Immunoassay Market Segmentation

The North America fluorescent immunoassay market is segmented into product type, application, end user, and country. Based on product type, the market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on application, the market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on country, the North America fluorescent immunoassay market is segmented into the US, Canada, and Mexico.

Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the North America fluorescent immunoassay market.

At 5.9% CAGR, the North America Fluorescent Immunoassay Market is speculated to be worth US$ 1,598.58 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the North America fluorescent immunoassay market was valued at US$ 1,072.41 million in 2021 and is expected to reach US$ 1,598.58 million by 2028, registering an annual growth rate of 5.9% from 2021 to 2028. Growing prevalence of chronic diseases and increasing demand for cell therapies are the critical factors attributed to the market expansion.

Chronic diseases and conditions are on the rise across the region. The need for costly chronic care is increasing, placing significant demands on healthcare systems. The rise in the aging population and changes in societal behavior contribute to a steady rise in these common and costly long-term health problems. The middle class is growing, and with the rise in urbanization, people are adopting a more sedentary lifestyle. This drives obesity rates and cases of diseases such as diabetes. The chronic kidney disease (CKD) is the 14th leading cause of death and is responsible for 1.2 million deaths each year. The increasing incidence of CKD is primarily associated with lifestyle disorders such as hypertension, cardiovascular disease, hormonal imbalances, and diabetes. Early detection and treatment are crucial, as progressive CKD is associated with unfortunate clinical consequences, including end-stage kidney disease (ESKD), cardiovascular diseases, and increased mortality. The diagnosis, prognosis, and control of chronic kidney disease are based on understanding the glomerular filtration rate (GFR). Cystatin-C is a better GFR marker than the commonly used creatinine. The fluorescence lateral flow immunoassay was developed and optimized to estimate the cystatin C value to calculate the glomerular filtration rate. The COVID-19 pandemic highlighted the need for rapid and accurate nucleic acid detection at the point-of-care. Fluorescence-based quantitative reverse transcription PCR (RT-qPCR) has high sensitivity and specificity, but turnaround times can be extended in part (ranging from hours to days) due to the need for nucleic acid purification and amplification. In addition, a maximum of people infected with SARS-CoV-2 develop mild or no symptoms. There is, therefore, an urgent need to develop rapid, simple, and high-throughput assays for the detection of nucleic acids. A standard fluorescence immunoassay system is a multiparametric, random access system that provides accurate and reliable diagnostic results. It is a system capable of performing qualitative and quantitative analyses of infections, respiratory diseases, and chronic diseases. A convenient user interface and laboratory information system (LIS)/ hospital information system (HIS) connectivity save valuable time, and ambiguous test results are a thing of the past as the analyzer automatically reads and interprets the results. A cut-off index provides a good reference point for medical decision-making. Therefore, there is a growing need for fluorescent immunoassays owing to the rising number of chronic diseases across the region.

On the contrary, disadvantages of fluorescent immunoassays hurdles the growth of North America fluorescent immunoassay market.

Based on product type, the North America fluorescent immunoassay market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA held 56.5% market share in 2021, amassing US$ 605.76 million. It is projected to garner US$ 932.25 million by 2028 to expand at 6.4% CAGR during 2021–2028.

Based on application, the North America fluorescent immunoassay market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment held 54.7% market share in 2021, amassing US$ 586.71 million. It is projected to garner US$ 904.33 million by 2028 to expand at 6.4% CAGR during 2021–2028.

Based on end user, the North America fluorescent immunoassay market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment held 42.3% market share in 2021, amassing US$ 453.14 million. It is projected to garner US$ 722.52 million by 2028 to expand at 6.9% CAGR during 2021–2028.

Based on country, the North America fluorescent immunoassay market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% market share in 2021. It was assessed at US$ 908.99 million in 2021 and is likely to hit US$ 1,376.96 million by 2028, exhibiting a CAGR of 6.1% during the forecast period.

Key players dominating the North America fluorescent immunoassay market are Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG,Sysmex Corporation, and Thermo Fisher Scientific Inc. among others.

In June 2021, Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of SARS-CoV-2 infections. The laboratory-based Elecsys SARS-CoV-2 Antigen test had earlier received CE mark and has recently obtained the import license from CDSCO. In Apr 2021, bioMérieux announced the CE marking of its innovative and fully-automated assays to diagnose dengue infection - VIDAS DENGUE NS1 Ag, VIDAS Anti-DENGUE IgM, VIDAS Anti-DENGUE IgG. These VIDAS DENGUE assays can be used independently to detect the viral antigen (NS1) and antibodies (IgM and IgG) produced by the host in response to the infection. These 3 serological tests are recommended by international guidelines.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Fluorescent Immunoassay Market – By Product Type

1.3.2 North America Fluorescent Immunoassay Market – By Application

1.3.3 North America Fluorescent Immunoassay Market – By End User

1.3.4 North America Fluorescent Immunoassay Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Fluorescent Immunoassay Market – Market Landscape

4.1 Overview

4.2 North America PEST Analysis

4.3 Expert Opinions

5. North America Fluorescent Immunoassay Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Prevalence of Chronic Diseases

5.1.2 Increasing Demand for Cell Therapies

5.2 Market Restraints

5.2.1 Disadvantages of Fluorescent Immunoassays

5.3 Market Opportunities

5.3.1 Extensive Usage in Cancer Diagnostics

5.4 Future Trends

5.4.1 Increase in Development of Fluorescent Dyes and Instruments

5.5 Impact Analysis

6. Fluorescent Immunoassay Market – North America Analysis

6.1 North America Fluorescent Immunoassay Marker Revenue Forecast and Analysis

7. North America Fluorescent Immunoassay Market Analysis – By Product Type

7.1 Overview

7.2 North America Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)

7.3 ELISA

7.3.1 Overview

7.3.2 ELISA: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

7.4 Rapid Lateral Flow Immunoassay

7.4.1 Overview

7.4.2 Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

7.5 Others

7.5.1 Overview

7.5.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

8. North America Fluorescent Immunoassay Market Analysis – By Application

8.1 Overview

8.2 North America Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)

8.3 Infectious Diseases

8.3.1 Overview

8.3.2 Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

8.4 Oncology

8.4.1 Overview

8.4.2 Oncology: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

8.5 Cardiovascular Disease

8.5.1 Overview

8.5.2 Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

9. North America Fluorescent Immunoassay Market Analysis – By End User

9.1 Overview

9.2 North America Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)

9.3 Hospitals & Clinics

9.3.1 Overview

9.3.2 Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

9.4 Diagnostic Centers

9.4.1 Overview

9.4.2 Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

9.5 Pharmaceutical & Biotechnology Companies

9.5.1 Overview

9.5.2 Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

9.6 Academic & Research Institutes

9.6.1 Overview

9.6.2 Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)

10. North America Fluorescent Immunoassay Market Analysis – By Country

10.1 Overview

10.1.1 North America Fluorescent Immunoassay Market Revenue and Forecasts to 2028, By Country (%)

10.1.1.1 US: Fluorescent Immunoassay Market – Revenue and Forecast to 2028 (USD million)

10.1.1.1.1 Overview

10.1.1.1.2 US: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

10.1.1.1.3 US: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

10.1.1.1.4 US: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

10.1.1.1.5 US: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

10.1.1.2 Canada: Fluorescent Immunoassay Market – Revenue and Forecast to 2028 (USD million)

10.1.1.2.1 Overview

10.1.1.2.2 Canada: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

10.1.1.2.3 Canada: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

10.1.1.2.4 Canada: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

10.1.1.2.5 Canada: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

10.1.1.3 Mexico: Fluorescent Immunoassay Market – Revenue and Forecast to 2028 (USD Million)

10.1.1.3.1 Overview

10.1.1.3.2 Mexico: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

10.1.1.3.3 Mexico: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

10.1.1.3.4 Mexico: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

10.1.1.3.5 Mexico: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

11. Industry Landscape

11.1 Overview

11.2 Organic Developments

11.2.1 Overview

11.3 Inorganic Developments

11.3.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Thermo Fisher Scientific Inc.

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Abbott

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 BD

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Danaher

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 bioMerieux SA

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Sysmex Corporation

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Siemens AG

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Ortho Clinical Diagnostics Holdings plc

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Quidel Corporation

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

13. Appendix

13.1 About the Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1.             North America Fluorescent Immunoassay Market –Revenue and Forecast to 2028 (USD Million)

Table 2.             US: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 3.             US: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 4.             US: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 5.             Canada: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 6.             Canada: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 7.             Canada: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 8.             Mexico: Fluorescent Immunoassay Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 9.             Mexico: Fluorescent Immunoassay Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 10.          Mexico: Fluorescent Immunoassay Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 11.          Organic Developments

Table 12.          Inorganic Developments

Table 13.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           North America Fluorescent Immunoassay Market Segmentation

Figure 2.           North America Fluorescent Immunoassay Market – By Country

Figure 3.           North America Fluorescent Immunoassay Market Overview

Figure 4.           North America Fluorescent Immunoassay Market, By Product Type

Figure 5.           North America Fluorescent Immunoassay Market, By Country

Figure 6.           North America PEST Analysis

Figure 7.           North America Fluorescent Immunoassay Market Impact Analysis of Driver and Restraints

Figure 8.           North America Fluorescent Immunoassay Market – Revenue Forecast and Analysis

Figure 9.           North America Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)

Figure 10.        North America ELISA: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 11.        North America Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 12.        North America Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 13.        North America Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)

Figure 14.        North America Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 15.        North America Oncology: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 16.        North America Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 17.        North America Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 18.        North America Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)

Figure 19.        North America Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 20.        North America Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 21.        North America Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 22.        North America Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 23.        North America Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)

Figure 24.        North America Fluorescent Immunoassay Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 25.        North America Fluorescent Immunoassay Market Revenue and Forecasts to 2028, By Country (%)

Figure 26.        US: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

Figure 27.        Canada: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

Figure 28.        Mexico: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)

The List of Companies - North America Fluorescent Immunoassay Market

● Abbott

● BD

● bioMerieux SA

● Danaher

● F. Hoffmann-La Roche Ltd.

● Ortho Clinical Diagnostics Holdings plc

● Quidel Corporation

● Siemens AG

● Sysmex Corporation

● Thermo Fisher Scientific Inc.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America fluorescent immunoassay market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the North America fluorescent immunoassay market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the fluorescent immunoassay market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TOP